What does Pacira BioSciences do and what are its main business segments?

What is Pacira BioSciences's gross profit margin?

What is Pacira BioSciences's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Pacira BioSciences year over year?

What were the key takeaways from Pacira BioSciences’s earnings call?

Did Pacira BioSciences beat or miss consensus estimates last quarter?

What were the key takeaways from Pacira BioSciences's earnings call?

What is the market's earnings forecast for Pacira BioSciences next quarter?

- **Revenue Growth**: 2025 revenue up 15% to $72 million, with EXPAREL volumes +7% in Q4. On track for 3 million+ patients/year by 2030.
- **Exclusivity & IP**: EXPAREL protected through 2039 with 21 patents, enabling steady growth.
- **Pipeline Momentum**: PCRX-201 Phase II ASCEND study to report safety and efficacy trends in late 2026; LG Chem partnership to launch EXPAREL in APAC in 2027.
- **Financial Strength**: 80% gross margin in Q4 2025, $238 million cash, and $150 million share buyback program.
- **Partnerships**: J&J MedTech to drive ZILRETTA growth; LG Chem to expand EXPAREL into APAC markets.

**【CEO Summary Section】**
- Pacira achieved $72 million in 2025 revenue, up 15% YoY, driven by EXPAREL volume growth of 7% in Q4. The company exceeded its 5x30 goal of helping 2.5 million patients annually, with a target of 3 million by 2030.
- EXPAREL's exclusivity extended to 2039 via a Fresenius settlement, with 21 patents across 2 IP families. The J&J MedTech partnership expanded ZILRETTA's reach, while LG Chem secured South Korea/Thailand rights for 2027+.
- Pipeline progress includes PCRX-201 (Phase II ASCEND study with 49 patients), PCRX-2002 (longer-acting bupivacaine), and 3 preclinical HACd programs. The IGOR registry now tracks 3,200 OA patients.

**【CFO Financial Commentary】**
- Q4 2025 non-GAAP gross margin improved to 80% (vs. 79% in 2024), driven by higher EXPAREL production yields. Full-year 2026 guidance: $745-$770 million revenue, 77%-79% gross margin, $105-$115 million R&D spend, and $320-$330 million SG&A.
- Share buybacks reduced outstanding shares to 41 million, with $150 million remaining in the repurchase program.

**【Q&A Key Highlights】**
- **PCRX-201 Phase II ASCEND Study**: End-of-year 2026 data will focus on safety and efficacy trends (NRS pain scores, WOMAC, KOOS) vs. short-acting steroid comparator. Not powered for statistical significance but may inform accelerated development.
- **EXPAREL Growth**: 2026 guidance of $600-$620 million reflects steady cadence, with Q1 2026 volumes impacted by January/February storms. 102 million lives covered outside surgical bundles as of Q4 2025, expanding to 110 million+ in early 2026.
- **ZILRETTA Partnership**: J&J MedTech's fully trained sales force targets 2026 growth, leveraging ZILRETTA's consistent reimbursement vs. viscosupplements.
- **Business Development Costs**: Q4 2025 included $22 million in unanticipated costs for due diligence and litigation. Future deals will focus on accretive, derisked assets.


Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 6% YoY driven by 9% EXPAREL volume (highest in 3 years) and 82% gross margin
- **Strategic Investments**: $50M share buyback, AMT-143 licensing for 14-day analgesia, and Phase II PCRX-201 gene therapy
- **Pipeline Momentum**: 100M+ covered lives for EXPAREL, 3-year OA registry data showing opioid reduction, and J&J partnership accelerating Zilretta adoption
- **Risk Mitigation**: 21st EXPAREL patent and disciplined IP defense against generics

**【Management Opening Remarks】**
- CEO Frank Lee highlighted 6% year-over-year revenue growth, driven by 9% volume growth in EXPAREL and 82% non-GAAP gross margin. The company emphasized its 5x30 strategy for 5-year, 30% CAGR growth through commercial expansion and pipeline innovation.

**【CEO Commentary】**
- Reported strong execution across commercial and clinical initiatives, including EXPAREL volume growth of 9% (highest in 3 years) and 100 million+ covered lives via separate reimbursement policies. Discussed strategic investments in AMT-143 (long-acting bupivacaine) and Phase II PCRX-201 gene therapy for OA pain. Highlighted 21st EXPAREL patent listing and disciplined IP protection against generics.

**【CFO Financial Commentary】**
- GAAP net income: $420M; Non-GAAP EPS: $1.08 (vs. $0.95 prior). Gross margin improved to 82% (vs. 78% prior) due to manufacturing scale. R&D/Sales & Marketing expenses: $22.5M/$81.7M, up 30% YoY. Completed $50M share buyback, with $200M remaining under 2026 authorization. Raised 2025 guidance: Revenue $725M-$735M, EBITDA $49.4M.

**【Q&A Highlights】**
- **GPO Impact**: 9% EXPAREL volume growth offset by 3% ASP decline; expect convergence of volume/revenue growth in 2026. 
- **AMT-143 Licensing**: 14-day analgesia via hydrogel depot; Phase II planned for 2026. 
- **Zilretta Momentum**: J&J partnership driving access; 2026 Phase II for shoulder OA. 
- **Gene Therapy Perception**: PCRX-201 safety data (no neutralizing antibodies) and 3-year durability reduce skepticism.

Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript

- **Revenue Growth Acceleration**: Q2 EXPAREL volume up 6% YoY, narrowing full-year guidance to $730-750 million.
- **Gross Margin Expansion**: Q2 non-GAAP gross margin improved to 82%, with 2025 guidance raised to 78-80%.
- **Strategic Partnership Impact**: J&J MedTech collaboration doubles ZILRETTA reach, targeting 2026 growth in sports medicine and rheumatology.
- **Pipeline Momentum**: PCRX-201 Phase II study on track, with 3-year data showing sustained efficacy and safety.
- **Financial Strength**: $54.3 million adjusted EBITDA, $250 million remaining under share buyback program.

**【CEO Summary Section】**
- **Revenue Growth and Strategy**: Q2 2025 revenue growth driven by 6% year-over-year volume increase for EXPAREL, narrowing full-year guidance to $730-750 million. Emphasis on 5x30 strategy (5 partnerships by 2030) and pipeline innovation, including PCRX-201 with 3-year data showing sustained efficacy.
- **Market Access and IP**: CMS policy changes enabling outpatient EXPAREL use, with 40 million commercial lives covered (targeting 60 million by year-end). IP portfolio strengthened with reissued 495 patent and new erucic acid patents.
- **Partnerships**: J&J MedTech collaboration for ZILRETTA doubles sales reach, targeting sports medicine, pain management, and rheumatology markets.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q2 non-GAAP gross margin improved to 82% (vs. 76% in 2024), driven by manufacturing efficiencies. Adjusted EBITDA of $54.3 million. Share buybacks of $50 million executed, with $250 million remaining under 2026 authorization.
- **Expense Management**: R&D up 34% to $24.7 million (due to PCRX-201 Phase II study), SG&A up 31% to $77.2 million (commercial investments). New $300 million credit facility reduces interest costs by 60 basis points annually.
- **Guidance Update**: Full-year non-GAAP gross margin raised to 78-80% (from 76-78%), reflecting royalty elimination and cost savings.

**【Q&A Key Highlights】**
- **J&J Partnership Economics**: Doubling ZILRETTA sales calls, with benefits expected in 2026. J&J's broader customer base expands access to sports medicine and rheumatology segments.
- **Gross to Net Impact**: Low single-digit (1%) impact on margins, manageable within guidance.
- **Pipeline Progress**: PCRX-201 Phase II ASCEND study on track for Part A completion by year-end, with 3-year data showing sustained efficacy and safety.
- **Surgery Volumes**: Outpatient case volumes slightly down Q2 vs. 2024, but EXPAREL growth outpacing market in community hospitals and ASCs.
- **International Expansion**: Actively pursuing partnerships for EXPAREL, ZILRETTA, and iovera°, targeting leaders in musculoskeletal pain markets.

Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript

- **EXPAREL Exclusivity Extended to 2039**: Settlement with Fresenius eliminates RDF royalties, improving gross margin by low single digits.
- **Gene Therapy Breakthrough**: PCRX-201 Phase 1 data shows 2-year pain reduction in knee OA, with 3-year follow-up data coming in 2025.
- **Robust Cash Flow**: $494M cash balance and $300M buyback program reflect confidence in 5x30 growth strategy.
- **Pipeline Investment**: 50%+ R&D spend on PCRX-201, with HCAd platform enabling novel local delivery for chronic pain.

**【CEO Opening Remarks】**
- **5x30 Strategy Progress**: Settled EXPAREL patent litigation with Fresenius, extending exclusivity to 2039. 18th patent listed in FDA Orange Book, eliminating RDF royalties (low single-digit margin improvement). Phase 2 PCRX-201 trial for knee OA dosing underway. GQ Bio acquisition adds gene therapy platform with 30,000bp DNA capacity.
- **EXPAREL Growth**: Q1 sales $136.5M (+3.1% YoY), daily volume +7% (adjusted for 2 fewer days). New J-code adoption driving 30%+ account expansion in ASCs and community hospitals. Gross margin benefit from RDF royalty elimination (~low single-digit %).
- **Pipeline Momentum**: PCRX-201 Phase 1 data shows 2-year pain reduction in knee OA (KL grade 4). HCAd platform enables local delivery with 10x lower dose than AAV vectors. ASCEND trial enrollment on track for 2026 readout.

**【CFO Financial Highlights】**
- **Revenue**: Q1 total revenue $164.9M (+3.1% YoY). EXPAREL +3.1%, ZILRETTA -9%, iovera +2%. Q1 2025 guidance reaffirmed ($725-765M).
- **Margins**: Non-GAAP gross margin 81% (vs. 72% 2024), driven by San Diego manufacturing scale. R&D expense $23.1M (+41% YoY) for PCRX-201 and ZILRETTA shoulder trial. SG&A $76.2M (+20% YoY) for commercial expansion.
- **Cash Flow**: $494M cash balance. $300M share buyback authorized (2025-2026). 2025 capex ~$20M for manufacturing capacity.

**【Q&A Key Takeaways】**
- **EXPAREL Penetration**: ~9% of 18M no pain-eligible procedures. Medicare accounts ~50% in hospitals, 75% in ASCs. 2025 growth driven by ASC adoption and IDN formulary wins.
- **Pipeline Capital Allocation**: 50%+ R&D spend on PCRX-201. HCAd platform could enable partnerships for non-core indications (e.g., spasticity, diabetic neuropathy).
- **Tariff Risk**: <10% of manufacturing in China, no material impact expected.
- **GPO Impact**: 2025 GPO contracts may reduce EXPAREL pricing by mid-single digits, offset by volume growth.
- **201 Clinical Feedback**: Docs seek 12+ months efficacy vs. current 3-6 months. PCRX-201 3-year data to be presented in 2025.


Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript

- **Record 2024 Growth**: $701M revenue, 5/30 strategy launched with 3+ million patient target by 2030.
- **EXPAREL Momentum**: J-code adoption, 40M+ commercial covered lives, 80% GPO coverage.
- **Pipeline Breakthroughs**: PCRX-201 Phase II study active, HCAd platform for gene therapy, 3-year data expected.
- **Financial Discipline**: 2025 guidance of $725M-$765M, 76%-78% gross margin, $125M buyback flexibility.
- **Innovation Focus**: $90M-$105M R&D investment for pipeline expansion, 5 partnerships sought.

**【CEO Summary Section】**
- Pacira achieved record 2024 revenue of $701 million, driven by EXPAREL, Zilretta, and iovera. Key milestones include CMS coverage for EXPAREL and iovera, RMAT designation for PCRX-201, and 72-patient Phase 1 data showing 2-year efficacy.
- 5/30 Strategy: Target 3+ million patients annually by 2030, double-digit CAGR, 5% gross margin expansion, 5 pipeline programs, and 5 partnerships.
- EXPAREL: J-code adoption early signs positive, 40M+ commercial covered lives, GPO contracts covering 80% of volume.
- Zilretta: Shoulder OA Phase III study enrolling, 4-month pain relief, 40% diabetic patient opportunity.
- iovera: C-98-09 code reimbursement, SmartTip launch for low back pain, spasticity study underway.
- GQ Bio acquisition: HCAd platform for gene therapy, PCRX-201 Phase II study active, 3-year follow-up data expected.

**【CFO Financial Commentary】**
- Q4 2024: EXPAREL ($147.7M), Zilretta ($33.1M), iovera ($6.5M). Non-GAAP gross margin 79%, R&D ($22.0M), SG&A ($78.6M), adjusted EBITDA ($62.5M).
- 2025 Guidance: Revenue $725M-$765M, gross margin 76%-78%, R&D $90M-$105M (11% YoY increase), SG&A $290M-$320M (8% YoY increase). Capital allocation focused on growth, pipeline, balance sheet, and $125M buyback.

**【Q&A Highlights】**
- **No Pain Uptake**: Early J-code adoption, 40M+ commercial covered lives, but full impact expected in H2 2025. IQVIA data lag 4 months.
- **Litigation & IP**: No generic launch expected, ongoing IP enforcement. New patents anticipated.
- **DTC Marketing**: Pilot programs launching H1 2025, ROI-driven investment to drive patient demand.
- **Pipeline Risk**: GQ Bio platform adds 5 preclinical programs, HCAd vector advantages (30kbp payload, lower dosing).

Actual											0.53	0.12	0.68	0.87	0.53	0.77	0.72	0.97	0.64	0.51	0.64	0.8	0.53	0.78	0.72	0.89	0.62	0.89	0.79	0.91	0.62	0.74	0.7	0.57
Forecast											0.298	0.0929	0.6514	0.825	0.6354	0.7058	0.65	0.903	0.8318	0.8522	0.7666	0.8295	0.617	0.7587	0.7807	0.8833	0.6201	0.6989	0.7045	0.8353	0.5965	0.71	0.6775	0.9049
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+77.85%	+29.17%	+4.39%	+5.45%	-16.59%	+9.10%	+10.77%	+7.42%	-23.06%	-40.15%	-16.51%	-3.56%	-14.10%	+2.81%	-7.78%	+0.76%	-0.02%	+27.34%	+12.14%	+8.94%	+3.94%	+4.23%	+3.32%	-37.01%

Actual	--	--	--	--	--	--	--	--	--	--	105.68M	75.50M	117.48M	130.97M	119.03M	135.59M	127.72M	159.19M	157.99M	169.41M	167.47M	171.96M	160.34M	169.47M	163.93M	181.24M	167.12M	178.00M	168.57M	187.25M	168.92M	181.10M	179.52M	196.87M
Forecast	--	--	--	--	--	--	--	--	--	--	101.68M	72.08M	116.13M	131.66M	119.31M	132.48M	129.42M	156.29M	159.72M	170.64M	168.33M	171.94M	159.19M	174.85M	172.95M	180.62M	165.32M	173.70M	169.55M	184.70M	176.03M	183.07M	181.11M	200.33M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+3.94%	+4.75%	+1.17%	-0.52%	-0.24%	+2.34%	-1.31%	+1.86%	-1.09%	-0.72%	-0.51%	+0.01%	+0.73%	-3.08%	-5.22%	+0.35%	+1.09%	+2.47%	-0.57%	+1.38%	-4.04%	-1.08%	-0.88%	-1.73%

PCRX

PCRX fundamentals

PCRX Q4 2025 Earnings

Earnings Call

You can ask Aime

PCRX

PCRX fundamentals

PCRX Q4 2025 Earnings

Earnings Call

PCRX Earnings Call Summary for Q4/20254:30 PM on Feb 26, 2026

PCRX Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

PCRX Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

PCRX Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

PCRX Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

You can ask Aime